| 117 |
Dong-A ST Incorporates NeuroBo Pharmaceuticals as a Subsidiary |
2022-12-23 |
| 116 |
Dong-A ST Celebrates 20th Anniversary of Natural Medicine Stillen Tab |
2022-12-05 |
| 115 |
Dong-A ST Completes Global Phase 3 Trial for Stelara Biosimilar DMB-3115 |
2022-11-17 |
| 114 |
Dong-A ST Raises $32.3 Million Investment for NeuroBo Pharmaceuticals |
2022-11-09 |
| 113 |
Dong-A ST Signs Out-Licensing Agreement with Turkey’s Polifarma for Biosimilar DA-3880 |
2022-11-07 |
| 112 |
Dong-A ST Launches Korea’s First Liquid Injection Anti-Ulcer Drug Gaster Injection 20mg |
2022-11-03 |
| 111 |
Dong-A ST Announces KRW 10 Billion Share Buyback Plan |
2022-10-26 |
| 110 |
Dong-A ST Presents "Research on Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations" at EASD |
2022-10-12 |
| 109 |
Dong-A ST Signs MOU with Korea National Enterprise for Clinical Trials to Bring Medicines into the Korean Market |
2022-10-06 |
| 108 |
Dong-A ST Signs Global Out-Licensing and Investment Agreement with NeuroBo Pharmaceuticals |
2022-09-15 |
